Ingredient intelligence report
Ingredient hub · not a branded product review
Verdict
Studies conflict or are small; some plausible benefits, but the signal is too noisy for strong claims.
Last updated: 28 mars 2026
Overall
Trust score summarizes evidence, safety, and hype gap in our fixed rubric - not a personal recommendation.
Best for
Six editorial checks applied to every published hub. Status reflects our fixed scoring bands, not a product lab test.
Human data exist but are uneven, narrow, or contested for the loudest claims.
Dosage discussion is documented on this hub; compare any bottle to studied ranges yourself.
Some gap between marketing certainty and trial endpoints remains visible.
This page is an ingredient hub (not a SKU review). Transparency is judged at the evidence-and-claim level, not for a single brand label.
Evidence is partial, industry-skewed, or not yet convincing at scale.
Fewer prominent red flags in conventional-use discussions - still not individualized risk clearance.
Formula
Human data quality varies by indication and extract. Registry evidence tier: medium. Use the evidence score on this page as a directional read, not a substitute for systematic reviews for your specific question.
NR (nicotinamide riboside)
Listed dose (hub)
See dosage notes (varies by product)
Some human data exist, but trials are small, heterogeneous, or not aligned with popular claims.
Why it matters
Retail products vary by salt form, dose, and purity. The hub anchors what the compound can claim in evidence - not every bottle on the shelf.
Credibility
Editorial read of marketing narratives versus trial support and safety context. Not a regulatory finding.
Typical storefront and social narratives versus what human data actually test.
Where messaging tends to outrun endpoints, populations, or replication in trials.
Economics
Ingredient hubs are not pegged to a single SKU or live price feed. The read below ties value posture to evidence and hype - not checkout data.
Context-only valuation
Context-only read
No single retail price is evaluated here. Use evidence and hype signals to judge whether branded premiums are justified.
Higher overall score with equal or lower hype gap in our model - navigation hints, not medical advice or guaranteed substitutes.
Some links elsewhere on the site may earn a commission. Rankings and scores are not influenced by affiliate relationships.
Stronger composite score with contained hype versus NR (nicotinamide riboside) in this dataset.
Stronger composite score with contained hype versus NR (nicotinamide riboside) in this dataset.
Stronger composite score with contained hype versus NR (nicotinamide riboside) in this dataset.
Short answers for search intent. The analysis sections above carry the full nuance.
Literature
Human data quality varies by indication and extract. Registry evidence tier: medium. Use the evidence score on this page as a directional read, not a substitute for systematic reviews for your specific question.
Safety
Cautions (registry notes): Generally studied short/medium term; cancer theoretical NAD debate not settled. Always disclose supplements to clinicians when pregnant, breastfeeding, on anticoagulants, or managing diabetes, thyroid, seizure, or transplant medications.
Common products 300-1000 mg/day in studies. (typical supplement-label context, not individualized dosing).
Product-level dosing varies. This section is general context, not a prescription.
Shorter pages tuned to how people ask - each links back here for the full file.
A few hand-picked entry points around NR (nicotinamide riboside): categories, answers to narrow questions, and comparisons.
Grouped near NR (nicotinamide riboside) in the model - not interchangeable.
Soluble fiber with strong evidence for constipation and as a lipid adjunct in some guideline discussions when taken with water.
EPA/DHA support cardiovascular risk reduction contexts in some guidelines; supplements vary widely in quality and dose.
Fibers and oligosaccharides that selectively feed commensal microbes; strongest human stories sit in IBS-style and regularity contexts.
Swaps discussed alongside NR (nicotinamide riboside) - judge each on its own evidence.
No sponsored reviews
Editorial model. No paid verdicts.
Evidence-based analysis
Human trial signal, not storefront copy.
Continuously updated
Hubs revised as synthesis changes.
Scores compress ingredient evidence, dosage discussion, claim stress-testing, and hype gap. Outbound retailer links do not change the model output.
· ·